full
border
#666666
http://www.lennonsearch.com/wp-content/themes/smartbox-installable/
http://www.lennonsearch.com/
#26ADE4
style3
Over 25 Years Of Expertise
828-403-6096

Archive for March, 2014

31
Mar

AstraZeneca isn’t due to move into its new Cambridge, U.K., headquarters for another two years, but the British giant is already laying the groundwork for open collaboration in the biomedical hub, signing a deep-seated deal with the government-run Medical Research Council to work on drug discovery. …read more Source: AstraZeneca cozies up to MRC scientists […]

31
Mar

Lexington, MA-based Curis says the FDA has lifted the partial clinical hold on CUDC-427, which was instituted after the death of a patient in a Phase I study of solid tumors and lymphoma. …read more Source: FDA lifts a partial hold on Curis cancer drug     

31
Mar

The drug giant is pulling its application in Europe after concluding that the data didn’t paint a sufficiently positive portrait of overall survival benefits for patients–despite an improvement seen in progress-free survival. …read more Source: Glaxo scraps the ovarian cancer app for Votrient     

31
Mar

Small-cap Australian biotech Prana Biotechnology set out to vanquish a biomarker for Alzheimer’s disease in a Phase II study of a lead drug pursuing an odd avenue in fighting the disease. This morning, when it acknowledged that the study was a bust, the rout of investors popped its stock price, pumped up in a speculative […]

30
Mar

No matter how badly a drug fails in Phase III, investigators and the companies that employ them often bend over backwards to highlight any positive sign of efficacy, no matter how weak the signal. And GlaxoSmithKline’s team at the American College of Cardiology meeting over the weekend was in full spin mode with their heart […]

28
Mar

AstraZeneca has struck up a partnership with the Shenzhen University Health Science Center in Shanghai to collaborate on preclinical work for chronic kidney disease treatments, a growing problem among China’s aging population. …read more Source: AstraZeneca looks to China for kidney disease R&D     

default
Loading posts...
link_magnifier
#5C5C5C
off
fadeInDown
loading
#5C5C5C
off